Hospital Universitario Puerta de Hierro -ko ikertzaileekin lankidetzan egindako argitalpenak (36)

2024

  1. Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial

    Bone Marrow Transplantation

2023

  1. Changes in echocardiographic parameters over time in paradoxical low-flow low-gradient aortic stenosis

    European heart journal. Cardiovascular Imaging, Vol. 24, Núm. 8, pp. 1120-1128

  2. Clinical and Demographic Characteristics of Centenarians versus Other Age Groups Over 75 Years with Hip Fractures

    Clinical interventions in aging, Vol. 18, pp. 441-451

  3. Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern

    Journal of medical virology, Vol. 95, Núm. 3, pp. e28679

2022

  1. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 59

  2. Nurses competence in the reporting of medication-related incidents: An intervention study

    Nursing Open, Vol. 9, Núm. 6, pp. 2836-2846

  3. Prognosis of Paradoxical Low-Flow Low-Gradient Aortic Stenosis: A Severe, Non-critical Form, With Surgical Treatment Benefits

    Frontiers in Cardiovascular Medicine, Vol. 9

2021

  1. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia

    Journal of Clinical Investigation, Vol. 131, Núm. 20

  2. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

    BMC Cardiovascular Disorders, Vol. 21, Núm. 1

  3. Development of a new comprehensive preoperative risk score for predicting 1-year mortality in patients with hip fracture: the HULP-HF score. Comparison with 3 other risk prediction models

    HIP International, Vol. 31, Núm. 6, pp. 804-811

  4. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial

    Trials

  5. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial

    Trials, Vol. 22, Núm. 1

  6. The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation

    ESMO Open, Vol. 6, Núm. 3

2020

  1. A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality

    Antimicrobial Agents and Chemotherapy, Vol. 64, Núm. 9

  2. Adaptation and validation of the ICU Mobility Scale in Spain

    Enfermeria Intensiva, Vol. 31, Núm. 3, pp. 131-146

  3. EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma

    Oncologist, Vol. 25, Núm. 12, pp. 1067-1074

  4. Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study

    Clinical Rheumatology, Vol. 39, Núm. 9, pp. 2751-2756

  5. Impact of 68Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain

    Reports of Practical Oncology and Radiotherapy, Vol. 25, Núm. 3, pp. 405-411

  6. Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study

    CNS Drugs, Vol. 34, Núm. 12, pp. 1275-1286

  7. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population

    Journal of Neurology, Vol. 267, Núm. 8, pp. 2362-2371